Background. Limited data exist on factors predicting the development of opportunistic infections (OIs) at higher-than-expected CD4 + cell counts in human immunodeficiency virus (HIV) type 1-infected adults. Methods. Multivariate Poisson regression models were used to determine factors related to the development of groups of OIs above their respective traditional upper CD4 + cell count thresholds: group 1 (у100 cells/mL), OIs caused by cytomegalovirus, Mycobacterium avium complex, and Toxoplasma gondii; group 2 (у200 cells/mL), Pneumocystis pneumonia and esophageal candidiasis; and group 3 (у300 cells/mL), pulmonary and extrapulmonary tuberculosis.
risk of OIs in HIV-1-infected patients at all levels of immunodeficiency [2] . The risk of OIs is known to decrease with decreasing immunodeficiency [1, 3] . As a consequence, CD4 + cell count thresholds have been identified below which the risk of clinical progression and specific OIs is sufficiently high to warrant the initiation of CART and prophylaxis for opportunistic pathogens [4] . However, case reports and retrospective studies have suggested that a minority of HIV-1-infected patients develop OIs at higher-than-expected CD4 + cell counts during CART, when the immune function would appear to be only moderately compromised, if at all [5, 6] . Some infections (e.g., tuberculosis [TB] [7] ) can develop over a wide range of CD4 + cell counts and might also develop in persons without recognized immunodeficiency. Analyses of HIV-1-infected cohorts prior to the introduction of CART suggested that patients with high CD4 + cell counts with clinical signs of one OI were at excess risk of another [8] . Thus, several factors may influence the risk of developing OIs at relatively high CD4 + cell counts. These factors have, however, not been thoroughly investigated, and, to our knowledge, they have not been previously reported from large international cohort studies.
PATIENTS AND METHODS

Cohort.
The EuroSIDA study is a prospective observational study of HIV-1-infected patients from 82 centers in 28 European countries, Israel, and Argentina. Details of the study have been published elsewhere [2] . Six cohorts of patients have been recruited to date. Information was provided on a standardized data-collection form at recruitment and at 6-month intervals. Follow-up lasted through April 2005, and all CD4 + cell counts, plasma HIV-1 RNA levels, dates of starting and stopping each antiretroviral drug, and information about disease-specific chemoprophylaxis and treatment were routinely collected. Both CD4 + cell counts and HIV-1 RNA levels were measured at median intervals of 3 months (interquartile range [IQR], 2-4 months). Data on reasons for the initiation or discontinuation of disease-specific prophylaxis and adherence to antiretroviral drugs were not collected. AIDS-defining diagnoses were recorded, including distinct diagnoses made subsequent to the initial diagnosis, using the 1993 clinical definition of AIDS of the US Centers for Disease Control and Prevention [9] . An extensive quality-assurance program was established that included data quality control at the coordinating center and monitoring visits to each site.
Patients. Three groups of patients were defined a priori according to CD4 + cell count thresholds. Baseline was defined as the date of the first CD4 + cell count measurement above the predefined threshold. In group 1, patients were required to have at least 1 CD4 + cell count of у100 cells/mL during prospective follow-up in the EuroSIDA study. A diagnosis of cytomegalovirus (CMV) retinitis, Mycobacterium avium complex (MAC) infection, or cerebral toxoplasmosis (TOXO) was defined as the end point. In group 2, the CD4 + cell count threshold was у200 cells/mL, with an end point of Pneumocystis jirovecii pneumonia (PCP) or esophageal candidiasis (EC). In group 3, the CD4 + cell count threshold was у300 cells/mL, with an end point of pulmonary or extrapulmonary TB. Patients were excluded from their individual groups if they had no CD4 + cell counts recorded after baseline or had been given a diagnosis of any of the diseases that constituted the end point prior to baseline. We defined CART as any combination of у3 antiretroviral drugs that included at least 1 protease inhibitor, 1 nonnucleoside reverse-transcriptase inhibitor, or abacavir.
Statistical methods. Descriptive statistics were used to describe the baseline characteristics of the patients in each group and to describe patient characteristics at the date of diagnosis of the relevant OI. Characteristics of interest were CD4 + cell count, nadir of the CD4 + cell count, HIV-1 RNA (when available), previous and current antiretroviral therapy (ART), prior AIDS diagnosis, and use of disease-specific prophylaxis. Of note is the fact that patients could be included in 11 group.
At each CD4 + cell count measurement, follow-up since the last CD4 + cell count was calculated; person-years of follow-up (PYFU) accrued in 2 categories-above or below the CD4 + cell count threshold-and OIs were categorized in the same way. The incidence of OIs in each of the 3 groups was calculated using the latest, or "current," CD4 + cell count. Multivariate Poisson regression was used to determine the factors related to the development of the relevant OI in the 3 groups at a CD4 + cell count above the threshold level. Patients were removed from the analyses if their CD4 + cell counts fell below the threshold, and they were reinstated at the date when the CD4 + cell count returned to a level above the threshold. Therefore, events that occurred below the CD4 + cell count threshold were not included. Only the first OI within each group was included in the analyses. Factors included in univariate models were demographic factors (date of birth, ethnic origin, sex, country of origin, risk group, and region of Europe), current CD4 + cell count, nadir of the CD4 + cell count (either as a continuous or categorical variable, both of which were included as log 2 -transformed variables when modeled as continuous variables), time with CD4 + cell count below the threshold, starting CART, starting any ART, year of follow-up, and prior AIDS-defining diagnosis. Factors that were significant in univariate models ( ) were included in the multivariate P ! .1 model for the corresponding group. Factors that were not significant in univariate analyses were added in turn to the final model, to test whether they were confounding variables or were related to the development of the OI. All statistical analyses were performed using SAS software (version 9.1; SAS Institute). + cell count, HIV-1 RNA load, and age were defined at first CD4 + cell count above the threshold. HIV-1 RNA load data were available for 6380 patients in group 1 (69.2%), 5861 patients in group 2 (73.9%), and 6376 patients in group 3 (81.3%). HIV-1 RNA load !400 log 10 copies/mL was for 2782 (43.6%), 2712 (46.3%), and 3396 (53.3%) patients, respectively. ART, antiretroviral therapy; CART, combination antiretroviral therapy; IDU, injection drug user; IQR, interquartile range; MSM, men who have sex with men.
RESULTS
As
a Patients started some ART (ART/CART) but were receiving no ART at baseline. ). In group P p .010 3, patients with a diagnosis of TB had a considerably higher nadir of the CD4 + cell count than did those who did not develop TB (
). In all groups, patients who developed an OI P p .0006 had significantly higher HIV-1 RNA levels at baseline and were less likely to be receiving CART than were patients who did not develop an OI.
In all 3 groups, the incidence of OIs was significantly lower ). The median CD4 + cell count over the course of P p .0024 the entire follow-up period was significantly higher in patients who had started CART in all groups: in group 1, 410 cells/mL (IQR, 270-586 cells/mL) for patients who had started CART and 355 cells/mL (IQR, 242-496 cells/mL) for those who had not; in group 2, 456 cells/mL (IQR, 330-625 cells/mL) for patients who had started CART and 396 cells/mL (IQR, 300-531 cells/mL) for those who had not; and in group 3, 510 cells/mL (IQR, 400-670 cells/mL) for patients who had started CART and 459 cells/mL (IQR, 374-590 cells/mL) for those who had not ( ). P ! .0001 Figure 1 shows the incidence of OIs in each group according to the latest CD4 + cell count. In groups 1 and 2, there was a clear pattern of decreasing incidence of the OIs as the current Table 2 . Baseline characteristics of patients according to whether they developed opportunistic infections (OIs). . 
CD4
+ cell count increased, both above and below the threshold. For group 3, the incidence of TB was significantly higher when the CD4 + cell count decreased to !300 cells/mL. However, as the current CD4 + cell count increased to above this level, there were few changes in the incidence of TB, although a trend toward an inverse correlation between current CD4 + cell count and TB incidence was observed.
The median CD4 + cell count at diagnosis was 175 cells/mL (IQR, 120-266 cells/mL) in group 1, 302 cells/mL (IQR, 251-385 cells/mL) in group 2, and 444 cells/mL (IQR, 360-569 cells/ mL) in group 3, which is !2 times the predefined threshold. The median time between last CD4 + cell count and the diagnosis of an OI in all groups was 2 months (IQR, 1-5 months). Median HIV-1 RNA levels at the time of diagnosis were higher in group 1 (3.88 ) had a sig-P p .0092 nificantly reduced incidence of PCP or EC. The incidence of PCP or EC was 1.51 times higher in IDUs than in non-IDUs (95% CI, 1.04-2.21;
). Further analysis showed that P p .031 the increased incidence of PCP or EC in IDUs was mainly due to an increased incidence of EC rather than of PCP (data not shown).
In the multivariate model for group 3, the only predictors for the development of TB were starting CART and HIV-1 risk group; patients starting CART (IRR, 0.49 [95% CI, 0.25-0.96]; ) had a significantly reduced incidence of TB, and P p .037 IDUs had a significantly higher incidence of TB, compared with non-IDUs (IRR, 2.12 [95% CI, 1.07-4.21];
). P p .032 For the subset of patients with HIV-1 RNA levels available, subanalyses were performed to investigate whether the incidence of OIs was related to current HIV-1 RNA level after adjustment for the same variables presented in table 3. In all groups, a 1-log higher current HIV-1 RNA load was associated with an increased incidence of disease (for group 1, IRR, ). Additional adjustment for weight, in P p .93 a further reduced subset of patients, showed no relationship between current weight and the development of OIs in groups 1 and 2. In group 3, after adjustment for the variables shown in table 3 and current HIV-1 RNA load, a 5-kg weight loss was associated with a 20% increased incidence of TB (IRR, 1.20 [95% CI, 1.01-1.43];
). P p .044
DISCUSSION
The results of the present study show that current CD4 + cell count was the strongest predictor of the development of OIs at higher-than-expected CD4 + cell counts in patients with moderately to severely impaired immune function, as measured by CD4 + cell count (groups 1 and 2) . Furthermore, we found a strong inverse correlation between the use of CART and the development of OIs at higher-than-expected CD4 + cell counts that was independent of current CD4 + cell count. In group 3, patients infected via injection drug use had an increased risk of TB. Neither nadir nor baseline CD4 + cell counts nor the duration of severe immunodeficiency predicted the development of OIs in multivariate analyses.
To the best of our knowledge, this is the first study of the risk of OIs at higher-than-expected CD4 + cell counts, and the analyses suggest that the risk of OI is a continuum of progressively lower risk the higher the CD4 + cell count getssimilar to the situation in patients with CD4
+ cell counts within the expected range (figure 1) [10] [11] [12] . Although this continuum exists for all OIs, the differences in risk according to latest CD4 + cell count was less pronounced for TB than for the other OIs studied. The explanation for this difference could be that contraction of TB is more dependent on exposure group than on immunological status in patients who do not have severely impaired immune function. This is consistent with previous findings that IDUs develop TB more frequently than do persons in other exposure groups [13, 14] .
The CD4 + cell count thresholds chosen for groups 1-3 were all above the 75th percentile for development of the different OIs as identified in a study by Mocroft et al. [1] . OIs were grouped according to the range of CD4 + cell count at which the risk of occurrence is highest and the initiation of the disease-specific prophylaxis is recommended at the same CD4 + cell count level within each of the groups (except for TB, for which guidelines do not suggest a certain CD4 + cell count threshold) [4] . Our results show a beneficial effect of CART on the incidence of OIs at higher-than-expected CD4 + cell counts after controlling for the beneficial effect of CART on the number of CD4 + cells. These results are consistent with those of other studies, which showed that the beneficial effects of CART on reducing mortality and morbidity among HIV-1-infected patients cannot be fully explained by how this medication affects the number of CD4 + cells [2, [15] [16] [17] . The fact that some patients developed OIs after starting CART suggests that, despite the restoration of CD4 + cell counts, there remains a deficit in immune function that cannot be captured by the level of CD4 + cells alone. However, the positive effect of CART was eliminated after adjustment for HIV-1 RNA level, which suggests that the decreased incidence of OIs after the initiation of CART can be further explained by decreasing HIV-1 RNA load.
One of the study limitations, however, was that a limited number of patients received CART, and there was not sufficient power to repeat the analyses only for patients who started CART. There was no correlation between the calendar date of diagnosis of an OI in any group and the CD4 + cell count at diagnosis (data not shown), which suggests that the OIs diagnosed in each group after the widespread introduction of CART were not diagnosed at different levels of immunodeficiency. Longer prospective follow-up and a larger sample size are required to compare the risk of disease progression in treated and untreated patients at the same levels of CD4 + cells and with suppressed or unsuppressed HIV-1 RNA. The limited power and difficulties in diagnosis [18] also meant that it was not possible to evaluate the number of events in which immune reconstitution syndrome played a significant role in patients starting CART. Another limitation is that included centers are generally centers of excellence, and the cohort might not be representative of all HIV-1-infected adults in Europe, especially in Eastern Europe. Patients enrolled in the cohort are assumed to be more compliant to therapy than the general population. Thus, it is likely that we are underestimating the incidence of OIs at higher than expected CD4 + cell counts, particularly that of TB in IDUs. Furthermore, we have no data on current drug use, which may be an important surrogate for a lifestyle in which the risk of contracting TB is high.
Previously, a EuroSIDA study [19] and a study by Law et al. [5] reported a clear trend of increasing CD4
+ cell counts at the time of AIDS diagnosis over time from before to after the initiation of CART, although these analyses did not suggest that the increase was due to an increasing risk of a particular OI for a given CD4 + cell count [19] . However, few studies have investigated factors associated with the development of OIs at higher-than-expected CD4 + cell counts. In a EuroSIDA study by Miller et al. [20] , there was an association between disease progression (to AIDS or death) and nadir of the CD4 + cell count among patients with baseline CD4 + cell counts of у200 cells/mL. In that analysis, a time-updated (current) CD4 + cell count was not included. In contrast, our analysis did not demonstrate an association between the degree of previous immunosuppression and the risk of developing an OI.
In a nested case-control study, Hennessey et al. [21] investigated the development of AIDS at CD4 + cell counts of 1300 cells/mL. That study showed that, during the pre-CART era, the HIV-1 RNA level prior to a diagnosis of AIDS was significantly associated with a faster rate of disease progression, whereas no association was observed for immunological factors. The sample size in the study, however, was small (33 cases of AIDS, 52% of which were defined by the presence of Kaposi sarcoma). In our study, a clinically more-relevant analytic approach was used in a larger sample (232 OIs), with considerably longer prospective follow-up.
In summary, the present results provide important clinical information about the risk of OIs at higher-than-expected CD4 + cell counts. The incidence of OIs, particularly in groups 1 and 2, continued to decrease the further the CD4 + cell count increased from the threshold value. Thus, although OIs in groups 1 and 2 occurred infrequently at higher-than-expected CD4 + cell counts, the incidence was considerably smaller in patients whose current CD4 + cell count was twice that of the threshold level. In group 3, our results suggest that TB may be present in a person with a history of injection drug use and with clinical symptoms suggestive of TB.
Our data may be used as an argument in favor of the initiation and/or optimization of CART at higher CD4 + cell counts. However, it needs to be recognized that the decision of when to start CART should be based on a complex set of arguments, including potential benefits versus potential harm for earlier rather than deferred initiation. Further investigation and a better understanding of the factors associated with disease progression in patients with acceptable immune function will improve the management of HIV-1-infected patients with respect to the early recognition of OIs, the possible use of OI prophylaxis, and the use of CART, all of which may help to further reduce morbidity and mortality caused by chronic HIV-1 infection.
